John Sakys Sells 1,000 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) CFO John Sakys sold 1,000 shares of the stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $165.71, for a total value of $165,710.00. Following the completion of the transaction, the chief financial officer now directly owns 9,696 shares in the company, valued at approximately $1,606,724.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

John Sakys also recently made the following trade(s):

• On Thursday, March 9th, John Sakys sold 400 shares of Mesa Laboratories stock. The shares were sold at an average price of $169.97, for a total value of $67,988.00.
• On Thursday, February 9th, John Sakys sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $184.27, for a total value of $184,270.00.
• On Monday, January 23rd, John Sakys sold 2,100 shares of Mesa Laboratories stock. The shares were sold at an average price of $210.19, for a total value of $441,399.00.

Mesa Laboratories Stock Down 2.0 %

Shares of Mesa Laboratories stock opened at $165.48 on Friday. Mesa Laboratories, Inc. has a 1 year low of $114.21 and a 1 year high of $268.38. The business has a 50-day moving average of $181.47 and a two-hundred day moving average of $165.86. The company has a market capitalization of $884.66 million, a P/E ratio of -570.62 and a beta of 0.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.74 and a quick ratio of 1.93.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 15th. Shareholders of record on Tuesday, February 28th were issued a $0.16 dividend. The ex-dividend date of this dividend was Monday, February 27th. This represents a $0.64 annualized dividend and a dividend yield of 0.39%. Mesa Laboratories’s dividend payout ratio (DPR) is currently -220.69%.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Mesa Laboratories in a research note on Thursday. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On Mesa Laboratories

Several large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company increased its holdings in shares of Mesa Laboratories by 3.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 1,987 shares of the medical instruments supplier’s stock worth $330,000 after acquiring an additional 57 shares in the last quarter. Mackenzie Financial Corp grew its holdings in shares of Mesa Laboratories by 5.5% during the first quarter. Mackenzie Financial Corp now owns 1,183 shares of the medical instruments supplier’s stock worth $302,000 after buying an additional 62 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Mesa Laboratories by 0.4% during the third quarter. Alliancebernstein L.P. now owns 14,479 shares of the medical instruments supplier’s stock worth $2,039,000 after buying an additional 63 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Mesa Laboratories by 4.8% during the fourth quarter. Arizona State Retirement System now owns 1,500 shares of the medical instruments supplier’s stock worth $249,000 after buying an additional 69 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in shares of Mesa Laboratories by 5.5% during the second quarter. LPL Financial LLC now owns 1,335 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 70 shares in the last quarter. 93.00% of the stock is currently owned by institutional investors.

About Mesa Laboratories

(Get Rating)

Mesa Laboratories, Inc engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development.